Show simple item record

dc.creatorVezmar, Sandra
dc.creatorMiljković, Branislava
dc.creatorVučićević, Katarina
dc.creatorTimotijević, Ivana
dc.creatorProstran, Milica
dc.creatorTodorović, Zoran
dc.creatorPokrajac, Milena
dc.date.accessioned2019-09-02T11:17:38Z
dc.date.available2019-09-02T11:17:38Z
dc.date.issued2009
dc.identifier.issn1347-8613
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1232
dc.description.abstractAlthough often necessary for obtaining remission following major depressive disorder, combined antidepressant treatment Is frequently associated with drug interactions and enhanced adverse drug effects. We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability. Twenty-two inpatients with major depression [Hamilton Depression Scale (HAM-D) rating >= 18] were treated with either amitriptyline (75 mg/day), fluvoxamine (100 mg/day) or both. Blood samples, for determination of amitriptyline, its major metabolite nortritpyline, and fluvoxamine, were obtained after single dose administration and in steady-state. Therapeutic efficacy was evaluated using HAM-D and adverse drug effects were evaluated using the clinical global impression scale. Following combined treatment, steady-state plasma levels of nortriptyline were significantly decreased compared to monotherapy. HAM-D scores after two-week treatment showed that there was a better response to combined treatment. There was no significant difference in severity of adverse effects among groups. We observed a pharmcokinetic interaction between fluvoxamine and amitritpyline resulting in impaired metabolism of the later. However, no signifcant impact of the interaction on treatment safety was observed. Moreover, concomitant use of amitriptyline at 75mg/day and fluvoxamine at 100 mg/day was well tolerated with a more prompt and stronger onset of clinical response compared to monotherapy in patients with major depression.en
dc.publisherJapanese Pharmacological Soc, Kyoto
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/145001/RS//
dc.rightsopenAccess
dc.sourceJournal of Pharmacological Sciences
dc.subjectamitriptylineen
dc.subjectfluvoxamineen
dc.subjectefficacyen
dc.subjectsafetyen
dc.subjectinteractionen
dc.titlePharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depressionen
dc.typearticle
dc.rights.licenseBY-NC-ND
dcterms.abstractВезмар, Сандра; Миљковић, Бранислава; Тимотијевић, Ивана; Тодоровић, Зоран; Покрајац, Милена; Простран, Милица; Вучићевић, Катарина;
dc.citation.volume110
dc.citation.issue1
dc.citation.spage98
dc.citation.epage104
dc.citation.other110(1): 98-104
dc.citation.rankM22
dc.identifier.wos000266351400011
dc.identifier.doi10.1254/jphs.09013FP
dc.identifier.pmid19444001
dc.identifier.scopus2-s2.0-66349112356
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/182/1230.pdf
dc.identifier.rcubconv_2149
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record